Johnson & Johnson stock (US4781601046): Q1 earnings beat with raised FY guidance

Johnson & Johnson reported Q1 2026 EPS of $2.70, beating estimates by $0.02, with revenue up 9.9% to $24.06B. Shares trade at $221.17 on NYSE as of May 8, 2026.

Johnson & Johnson released its Q1 2026 earnings on April 14, 2026, posting adjusted EPS of $2.70, surpassing the consensus estimate of $2.68 by $0.02. Quarterly revenue climbed 9.9% year-over-year to $24.06 billion, exceeding expectations of $23.60 billion, MarketBeat as of April 14, 2026. The company also raised its full-year 2026 guidance, projecting EPS of $11.45-$11.65 versus consensus $11.56, and revenue of $100.3-$101.3 billion against $100.5 billion expected.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare / Pharmaceuticals
• Headquarters/country: New Brunswick, New Jersey, USA
• Core markets: US, Europe, Asia
• Key revenue drivers: Innovative Medicine, MedTech
• Home exchange/listing venue: NYSE (JNJ)
• Trading currency: USD

Johnson & Johnson: core business model

Johnson & Johnson operates as a diversified healthcare company with two main segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals, including immunology, oncology, neuroscience, cardiovascular, and infectious diseases. MedTech covers surgical procedures, orthopaedics, vision care, and interventionist solutions. This structure, post the 2023 spin-off of consumer health into Kenvue, allows focused innovation in high-growth areas, MarketBeat as of May 2026.

The company generates revenue through product sales, licensing, and partnerships globally, with a strong emphasis on R&D investment exceeding $15 billion annually in recent years. Its business model relies on a robust pipeline of approved drugs and devices, supported by a AAA-rated balance sheet.

Main revenue and product drivers for Johnson & Johnson

Innovative Medicine drove much of Q1 growth, with key products like Darzalex (for multiple myeloma) and Stelara (immunology) contributing significantly. MedTech saw gains from robotics and orthopaedics. For FY 2025 reported earlier, annual revenue reached $96.36 billion with net income of $26.80 billion, per trailing data published with Q1 2026 results on April 14, 2026, MarketBeat as of April 14, 2026.

Trailing twelve-month EPS stands at $8.65, with a forward P/E around 25.57 based on expected growth to $12.58 next year. Dividend yield is approximately 2.3%, appealing to income-focused US investors tracking NYSE:JNJ.

Industry trends and competitive position

The healthcare sector faces patent cliffs but benefits from aging populations and biotech advances. Johnson & Johnson holds a top position with a market cap over $530 billion as of May 8, 2026, trading at $221.17 on NYSE, down 0.60% that day amid broader market moves, MarketBeat as of May 8, 2026. Competitors include Pfizer, Merck, and Medtronic.

Why Johnson & Johnson matters for US investors

As a NYSE-listed blue-chip with heavy US exposure—headquartered in New Jersey and deriving substantial revenue from American markets—Johnson & Johnson offers stability amid economic cycles. Its role in US healthcare innovation, from vaccines to medical devices, ties directly to domestic policy and spending trends.

Conclusion

Johnson & Johnson's Q1 2026 results highlight resilient growth and upbeat guidance, with EPS and revenue beats underscoring operational strength. The stock's position on NYSE provides US investors access to a healthcare leader amid sector tailwinds. Market reactions and future quarters will shape near-term performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.